ScholarIQanswers from OpenAlex & ORCID
J. Doyen
ResearcherPublications, citations & collaboration network
J. Doyen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does J. Doyen have?
ScholarIQindexed works
J. Doyen has 255 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does J. Doyen have?
ScholarIQcitation count
J. Doyen has 3,014 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of J. Doyen?
ScholarIQh-index
J. Doyen has an h-index of 29 in OpenAlex.
What is the i10-index of J. Doyen?
ScholarIQi10-index
J. Doyen has an i10-index of 62 in OpenAlex.
What is the ORCID of J. Doyen?
ScholarIQorcid
The ORCID for J. Doyen is on the source record.
What is the OpenAlex record for J. Doyen?
ScholarIQopenalex
The OpenAlex for J. Doyen is on the source record.
What are the most-cited papers on J. Doyen?
ScholarIQmost cited works
Prognostic factors in 1038 women with metastatic breast cancer
R. Largillier, Jean-Marc Ferrero, J. Doyen, Jérôme Barrière, M. Namer, Véronique Mari, A. Courdi, Jean‐Michel Hannoun‐Lévi, F. Ettore, Isabelle Birtwisle‐Peyrottes, C. Balu–Maestro, Pierre Yves Marcy, I. Raoust, M. Lallement, Emmanuel Chamorey
MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines
Sébastien Grosso, J. Doyen, Scott K. Parks, Thomas Bertero, Alexandra Paye, Bruno Cardinaud, Pierre Gounon, Sandra Lacas‐Gervais, Agnès Noël, Jacques Pouysségur, Pascal Barbry, Nathalie M. Mazure, Bernard Mari
Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome
J. Doyen, C. Trastour, F. Ettore, Isabelle Peyrottes, N. Toussant, Jocelyn Gal, Karine Ilc, Damien Roux, Scott K. Parks, Jean-Marc Ferrero, Jacques Pouysségur
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
Carine El Sissy, Amos Kirilovsky, Marc Van den Eynde, Ana-Maria Mușină, Maria-Gabriela Aniței, Alfredo Romero, Florence Marliot, Audelaure Junca, J. Doyen, Bernhard Mlecnik, Nacilla Haicheur, Tessa Fredriksen, Christine Lagorce, Anne Jouret‐Mourin, Daniel Léonard, Frédéric Bibeau, Soledad Iseas, Enrique Roca, Ana Cabanne, Carlos Vaccaro, Juan Pablo Santino, Eduardo Huertas, David Tougeron, Carlos Carvalho, Nuno Figueiredo, Rodrigo Oliva Perez, Angelita Habr‐Gama, Viorel Scripcariu, Jean‐Pierre Gérard, Jérôme Galon, Guy Zeitoun, Franck Pagès
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
D. Azria, J. Doyen, Marta Jarlier, Isabelle Martel‐Lafay, Christophe Hennequin, Pierre-Luc Etienne, V. Vendrely, Éric François, G. Roche, Olivier Bouché, X. Mirabel, Bernard Denis, Laurent Mineur, Jean-François Berdah, Marc-André Mahé, Y. Bécouarn, Olivier Dupuis, Gérard Lledo, Jean‐François Seitz, Laurent Bedenne, S. Gourgou-Bourgade, Béata Juzyna, Thierry Conroy, J.P. Gérard